Dendrogenin A arises from cholesterol and histamine metabolism and shows cell differentiation and anti-tumour properties

Nature Communications

Volumn 4, Issue , 2013, Pages

  De Medina, Philippe ^a,b   Paillasse, Michael R ^a,b   Segala, Gregory ^a,c,d   Voisin, Maud ^a,c,d   Mhamdi, Loubna ^b   Dalenc, Florence ^a,c,d   Lacroix Triki, Magali ^c,d   Filleron, Thomas ^d   Pont, Frederic ^e   Saati, Talal Al ^f   Morisseau, Christophe ^g   Hammock, Bruce D ^g   Silvente Poirot, Sandrine ^a,c,d   Poirot, Marc ^a,c,d  

^a CANCER RESEARCH CENTER OF TOULOUSE   (France)

^b Affichem   (France)

^c UNIVERSITÉ DE TOULOUSE   (France)

^d INSTITUT CLAUDIUS REGAUD   (France)

^e Université Paul Sabatier   (France)

^f Plateforme GénoToul Anexplo   (France)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHOLESTEROL; DENDROGENIN A; HISTAMINE; HYDROLASE INHIBITOR; UNCLASSIFIED DRUG;

ALKALOID; CANCER; CELL ORGANELLE; MAMMAL; METABOLISM; PROTEIN; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DRUG CONJUGATION; FEMALE; HISTAMINE METABOLISM; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; MOUSE; NONHUMAN;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY FLUIDS; BRAIN; CELL DIFFERENTIATION; CELL LINE, TUMOR; CHOLESTANOLS; CHOLESTEROL; EPOXIDE HYDROLASES; FEMALE; HISTAMINE; HUMANS; IMIDAZOLES; IMMUNOCOMPETENCE; LYMPHOCYTES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS; RECEPTORS, ESTROGEN; SURVIVAL ANALYSIS; TISSUE EXTRACTS;

ANIMALIA; MAMMALIA; MUS;

EID: 84878557557     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms2835     Document Type: Article

References (59)

1. Newman, J. W., Morisseau, C. & Hammock, B. D. Epoxide hydrolases: their roles and interactions with lipid metabolism. Prog. Lipid Res. 44, 1-51 (2005) (Pubitemid 40313218)
2. Poirot, M., Silvente-Poirot, S. & Weichselbaum, R. R. Cholesterol metabolism and resistance to tamoxifen. Curr. Opin. Pharmacol. 12, 683-689 (2012)
3. de Medina, P. et al. Importance of cholesterol and oxysterols metabolism in the pharmacology of tamoxifen and other AEBS ligands. Chem. Phys. Lipids 164, 432-437 (2011)
4. de Medina, P., Paillasse, M. R., Segala, G., Poirot, M. & Silvente-Poirot, S. Identification and pharmacological characterization of cholesterol-5,6-epoxide hydrolase as a target for tamoxifen and AEBS ligands. Proc. Natl Acad. Sci. USA 107, 13520-13525 (2010)
5. Payre, B. et al. Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism. Mol. Cancer Ther. 7, 3707-3718 (2008)
6. Kedjouar, B. et al. Molecular characterization of the microsomal tamoxifen binding site. J. Biol. Chem. 279, 34048-34061 (2004) (Pubitemid 39063057)
7. Silvente-Poirot, S. & Poirot, M. Cholesterol epoxide hydrolase and cancer. Curr. Opin. Pharmacol. 12, 696-703 (2012)
8. Porter, F. D. & Herman, G. E. Malformation syndromes caused by disorders of cholesterol synthesis. J. Lipid Res. 52, 6-34 (2011)
9. Segala, G. et al. 5,6-Epoxy-cholesterols contribute to the anticancer pharmacology of tamoxifen in breast cancer cells. Biochem. Pharmacol. (e-pub ahead of print 7 March 2013; doi:10.1016/j.bcp.2013.02.031)
10. de Medina, P. et al. Ligands of the antiestrogen-binding site induce active cell death and autophagy in human breast cancer cells through the modulation of cholesterol metabolism. Cell Death Differ. 16, 1372-1384 (2009)
11. Poirot, M. & Silvente-Poirot, S. Cholesterol-5,6-epoxides: chemistry, biochemistry, metabolic fate and cancer. Biochimie 95, 622-631 (2013)
12. Jordan, V. C. Chemoprevention of breast cancer with selective oestrogenreceptor modulators. Nat. Rev. Cancer 7, 46-53 (2007) (Pubitemid 46020846)
13. Guengerich, F. P. Cytochrome P450 oxidations in the generation of reactive electrophiles: epoxidation and related reactions. Arch. Biochem. Biophys. 409, 59-71 (2003) (Pubitemid 36042902)
14. Parker, R. E. & Isaacs, N. S. Mechanisms of epoxide reactions. Chem. Rev. 59, 737-799 (1959)
15. Paillasse, M. R. et al. Surprising unreactivity of cholesterol-5, 6-epoxides towards nucleophiles. J. Lipid Res. 53, 718-725 (2012)
16. Watabe, T. & Sawahata, T. Biotransformation of cholesterol to cholestane- 3beta,5alpha,6beta-triol via cholesterol alpha-epoxide (5alpha,6alphaepoxycholestan- 3beta-ol) in bovine adrenal cortex. J. Biol. Chem. 254, 3854-3860 (1979) (Pubitemid 9178797)
17. Berrodin, T. J. et al. Identification of 5{alpha},6{alpha}- epoxycholesterol as a novel modulator of liver x receptor activity. Mol. Pharmacol. 78, 1046-1058 (2010)
18. Song, C., Hiipakka, R. A. & Liao, S. Auto-oxidized cholesterol sulfates are antagonistic ligands of liver X receptors: implications for the development and treatment of atherosclerosis. Steroids 66, 473-479 (2001) (Pubitemid 32140924)
19. Meyer, D. J. & Ketterer, B. 5 alpha,6 alpha-Epoxy-cholestan-3 beta-ol (cholesterol alpha-oxide): A specific substrate for rat liver glutathione transferase B. FEBS Lett. 150, 499-502 (1982) (Pubitemid 13184096)
20. Watabe, T., Sawahata, T. & Horie, J. Evidence for the formation of a steroid S-glutathione conjugate from an epoxysteroid precursor. Biochem. Biophys. Res. Commun. 87, 469-475 (1979)
21. de Medina, P., Paillasse, M. R., Payre, B., Silvente-Poirot, S. & Poirot, M. Synthesis of new alkylaminooxysterols with potent cell differentiating activities: identification of leads for the treatment of cancer and neurodegenerative diseases. J. Med. Chem. 52, 7765-7777 (2009)
22. Brandes, L. J., Bogdanovic, R. P., Cawker, M. D. & LaBella, F. S. Histamine and growth: interaction of antiestrogen binding site ligands with a novel histamine site that may be associated with calcium channels. Cancer Res. 47, 4025-4031 (1987) (Pubitemid 17108464)
23. Dewick, P. M. Medicinal Natural Products: A Biosynthetic Approach (John Wiley & Sons, Ltd, New York, 2002)
24. Herbst, R. S. et al. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin. Cancer Res. 9, 4108-4115 (2003) (Pubitemid 37204027)
25. Li, D., Williams, J. I. & Pietras, R. J. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression. Oncogene 21, 2805-2814 (2002) (Pubitemid 34499377)
26. Williams, J. I. et al. Squalamine treatment of human tumors in nu/nu mice enhances platinum-based chemotherapies. Clin. Cancer Res. 7, 724-733 (2001) (Pubitemid 32707999)
27. Sills, Jr. A. K. et al. Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature. Cancer Res. 58, 2784-2792 (1998) (Pubitemid 28311909)
28. Gray, J. M. & Ziemian, L. Antiestrogen binding sites in brain and pituitary of ovariectomized rats. Brain Res. 578, 55-60 (1992)
29. Umetani, M. et al. 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat. Med. 13, 1185-1192 (2007) (Pubitemid 47530633)
30. Sato, H. et al. Oxysterol regulation of estrogen receptor alpha-mediated gene expression in a transcriptional activation assay system using HeLa cells. Biosci. Biotechnol. Biochem. 68, 1790-1793 (2004) (Pubitemid 39270534)
31. de Medina, P., Favre, G. & Poirot, M. Multiple targeting by the antitumor drug tamoxifen: a structure-activity study. Curr. Med. Chem. Anticancer Agents 4, 491-508 (2004) (Pubitemid 39406262)
32. de Medina, P. et al. The prototypical inhibitor of cholesterol esterification, Sah 58-035 [3-[decyldimethylsilyl]-n-[2-(4-methylphenyl)-1- phenylethyl] propanamide], is an agonist of estrogen receptors. J. Pharmacol. Exp. Ther. 319, 139-149 (2006)
33. Schroepfer, Jr. G. J. Oxysterols: modulators of cholesterol metabolism and other processes. Physiol. Rev. 80, 361-554 (2000) (Pubitemid 30060568)
34. Sorensen, P. W. et al. Mixture of new sulfated steroids functions as a migratory pheromone in the sea lamprey. Nat. Chem. Biol. 1, 324-328 (2005)
35. Moore, K. S. et al. Squalamine: an aminosterol antibiotic from the shark. Proc. Natl Acad. Sci. USA 90, 1354-1358 (1993) (Pubitemid 23058170)
36. Beattie, M. E., Veatch, S. L., Stottrup, B. L. & Keller, S. L. Sterol structure determines miscibility versus melting transitions in lipid vesicles. Biophys. J. 89, 1760-1768 (2005) (Pubitemid 41233531)
37. Lund, E. & Bjoerkhem, I. Down-regulation of hepatic HMG-CoA reductase in mice by dietary cholesterol: Importance of the DELTA.5 double bond and evidence that oxidation at C-3, C-5, C-6, or C-7 is not involved. Biochemistry 33, 291-297 (1994) (Pubitemid 24046526)
38. Xu, F. et al. Dual roles for cholesterol in mammalian cells. Proc. Natl Acad. Sci. USA 102, 14551-14556 (2005) (Pubitemid 41457095)
39. Bjo?rkhem, I. & Hansson, M. Cerebrotendinous xanthomatosis: An inborn error in bile acid synthesis with defined mutations but still a challenge. Biochem. Biophys. Res. Commun. 396, 46-49 (2010)
40. Villablanca, E. J. et al. Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nat. Med. 16, 98-105 (2010)
41. Bensinger, S. J. et al. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell 134, 97-111 (2008) (Pubitemid 351905740)
42. Fuda, H., Javitt, N. B., Mitamura, K., Ikegawa, S. & Strott, C. A. Oxysterols are substrates for cholesterol sulfotransferase. J. Lipid Res. 48, 1343-1352 (2007) (Pubitemid 47312036)
43. Chen, W., Chen, G., Head, D. L., Mangelsdorf, D. J. & Russell, D. W. Enzymatic reduction of oxysterols impairs LXR signaling in cultured cells and the livers of mice. Cell Metab. 5, 73-79 (2007) (Pubitemid 44933109)
44. Nalbandian, G. & Kovats, S. Understanding sex biases in immunity: effects of estrogen on the differentiation and function of antigen-presenting cells. Immunol. Res. 31, 91-106 (2005) (Pubitemid 40631381)
45. Nalbandian, G., Paharkova-Vatchkova, V., Mao, A., Nale, S. & Kovats, S. The selective estrogen receptor modulators, tamoxifen and raloxifene, impair dendritic cell differentiation and activation. J. Immunol. 175, 2666-2675 (2005) (Pubitemid 41113882)
46. Mesange, F. et al. Microsomal epoxide hydrolase of rat liver is a subunit of theanti-oestrogen-binding site. Biochem. J. 334(Pt 1): 107-112 (1998) (Pubitemid 28420978)
47. Silvente-Poirot, S. & Poirot, M. Cholesterol metabolism and cancer: the good, the bad and the ugly. Curr. Opin. Pharmacol. 12, 673-676 (2012)
48. Paillasse, M. R. et al. Signaling through cholesterol esterification: a new pathway for the cholecystokinin 2 receptor involved in cell growth and invasion. J. Lipid Res. 50, 2203-2211 (2009)
49. Baptissart, M. et al. Bile acids: from digestion to cancers. Biochimie 95, 504-517 (2013)
50. Danilo, C. & Frank, P. G. Cholesterol and breast cancer development. Curr. Opin. Pharmacol. 12, 677-682 (2012)
51. Folkerd, E. J. & Dowsett, M. Influence of sex hormones on cancer progression. J. Clin. Oncol. 28, 4038-4044 (2010)
52. Rose, T. E. et al. 1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain. J. Med. Chem. 53, 7067-7075 (2010)
53. Morisseau, C. et al. Development of metabolically stable inhibitors of mammalian microsomal epoxide hydrolase. Chem. Res. Toxicol. 21, 951-957 (2008) (Pubitemid 351644574)
54. Nanni, P., de Giovanni, C., Lollini, P. L., Nicoletti, G. & Prodi, G. TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma. Clin. Exp. Metastasis 1, 373-380 (1983) (Pubitemid 14221672)
55. Szatmari, T. et al. Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci. 97, 546-553 (2006) (Pubitemid 43811598)
56. Vantourout, P. et al. Specific requirements for Vgamma9Vdelta2 T cell stimulation by a natural adenylated phosphoantigen. J. Immunol. 183, 3848-3857 (2009)
57. Lee, J. et al. Mechanisms of melanogenesis inhibition by 2,5-dimethyl-4- hydroxy-3(2H)-furanone. Br. J. Dermatol. 157, 242-248 (2007) (Pubitemid 47083829)
58. Ando, H. et al. Possible involvement of proteolytic degradation of tyrosinase in the regulatory effect of fatty acids on melanogenesis. J. Lipid Res. 40, 1312-1316 (1999) (Pubitemid 29328534)
59. de Medina, P. et al. Auraptene is an inhibitor of cholesterol esterification and a modulator of estrogen receptors. Mol. Pharmacol. 78, 827-836 (2010).